海欣股份(600851.SH)：公司下属子公司海欣生物的APDC三期临床试验项目仍在推进中

Group 1 - The core point of the article is that HaiXin Co., Ltd. (600851.SH) has confirmed that its subsidiary, HaiXin Bio, is continuing to advance the Phase III clinical trial project for APDC [1] Group 2 - The company is actively engaging with investors through its interactive platform to provide updates on its clinical trial progress [1]